| Literature DB >> 33067264 |
Tomoaki Matsumori1, Yuzo Kodama2,3, Atsushi Takai1, Masahiro Shiokawa1, Yoshihiro Nishikawa1, Tomonori Matsumoto4, Haruhiko Takeda1, Saiko Marui1, Hirokazu Okada1, Tomonori Hirano1, Takeshi Kuwada1, Yuko Sogabe1, Nobuyuki Kakiuchi1, Teruko Tomono1, Atsushi Mima1, Toshihiro Morita1, Tatsuki Ueda1, Motoyuki Tsuda1, Yuki Yamauchi1, Katsutoshi Kuriyama1, Yojiro Sakuma1, Yuji Ota1, Takahisa Maruno1, Norimitsu Uza1, Hiroyuki Marusawa5, Ryoichiro Kageyama6, Tsutomu Chiba1,7, Hiroshi Seno1.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is frequently driven by aberrant KRAS activation and develops in the liver with chronic inflammation. Although the Notch signaling pathway is critically involved in ICC development, detailed mechanisms of Notch-driven ICC development are still unknown. Here, we use mice whose Notch signaling is genetically engineered to show that the Notch signaling pathway, specifically the Notch/Hes1 axis, plays an essential role in expanding ductular cells in the liver with chronic inflammation or oncogenic Kras activation. Activation of Notch1 enhanced the development of proliferating ductal cells (PDC) in injured livers, while depletion of Hes1 led to suppression. In correlation with PDC expansion, ICC development was also regulated by the Notch/Hes1 axis and suppressed by Hes1 depletion. Lineage-tracing experiments using EpcamcreERT2 mice further confirmed that Hes1 plays a critical role in the induction of PDC and that ICC could originate from PDC. Analysis of human ICC specimens showed PDC in nonneoplastic background tissues, confirming HES1 expression in both PDC and ICC tumor cells. Our findings provide novel direct experimental evidence that Hes1 plays an essential role in the development of ICC via PDC. SIGNIFICANCE: This study contributes to the identification of the cells of origin that initiate ICC and suggests that HES1 may represent a therapeutic target in ICC. ©2020 American Association for Cancer Research.Entities:
Year: 2020 PMID: 33067264 DOI: 10.1158/0008-5472.CAN-20-1161
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701